SEC Info - Acer Therapeutics Inc. - ‘8-K’ for 7/28/22

SEC Info℠

Home

Help

Please Sign In

Acer Therapeutics Inc. – ‘8-K’ for 7/28/22

On: Thursday, 7/28/22, at 9:00am ET · For: 7/28/22 · Accession #: 1564590-22-26793 · File #: 1-33004

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 7/28/22  Acer Therapeutics Inc.            8-K:8,9     7/28/22   12:307K                                   ActiveDisclosure/FA

Current Report — Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     42K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     21K 
 3: EX-99.2     Miscellaneous Exhibit                               HTML     42K 
 7: R1          Document and Entity Information                     HTML     49K 
10: XML         IDEA XML File -- Filing Summary                      XML     12K 
 8: XML         XBRL Instance -- acer-8k_20220728_htm                XML     15K 
 9: EXCEL       IDEA Workbook of Financial Reports                  XLSX      8K 
 5: EX-101.LAB  XBRL Labels -- acer-20220728_lab                     XML     60K 
 6: EX-101.PRE  XBRL Presentations -- acer-20220728_pre              XML     37K 
 4: EX-101.SCH  XBRL Schema -- acer-20220728                         XSD     18K 
11: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    20K 
12: ZIP         XBRL Zipped Folder -- 0001564590-22-026793-xbrl      Zip     29K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C: C: C: C: C: C:

i false i 0001069308 0001069308 2022-07-28 2022-07-28

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM i 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): i July 28, 2022

i ACER THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

i Delaware		i 001-33004		i 32-0426967
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

i One Gateway Center, i Suite 356 i 300 Washington Street i Newton, i Massachusetts		i 02458
(Address of principal executive offices)		(Zip Code)
Registrant’s telephone number, including area code: ( i 844) i 902-6100
N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

i ☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i ☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i ☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i ☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
i Common Stock, $0.0001 par value per share	i ACER	i The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01.Other Events

On July 28, 2022, Acer Therapeutics Inc. issued press releases entitled “Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs” and “Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease,” copies of which are attached as Exhibit 99.1 and Exhibit 99.2 hereto and are incorporated herein by reference.

Item 9.01.Financial Statements and Exhibits.

(d) Exhibits


Exhibit No.		Description


99.1		Press release issued by Acer Therapeutics Inc. dated July 28, 2022, entitled “Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs.”

99.2		Press release issued by Acer Therapeutics Inc. dated July 28, 2022, entitled “Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease.”

104		Cover page interactive data file (embedded within the inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: July 28, 2022	ACER THERAPEUTICS INC.

	By:	/s/ *Harry S. Palmin*
		Harry S. Palmin
		Chief Financial Officer

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed on / For Period end:	7/28/22	None on these Dates
		List all Filings

2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/23/23  Acer Therapeutics Inc.            424B5                  1:460K                                   Donnelley … Solutions/FA
 2/07/23  Acer Therapeutics Inc.            424B2                  1:403K                                   Donnelley … Solutions/FA

↑Top

Filing Submission 0001564590-22-026793 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)